Development of Epigenetic Targeted Therapies in Hematological Malignancies: From Serendipity to Synthetic Lethality

Thomas Prebet; Steven D. Gore

doi:10.1016/B978-0-12-800206-3.00008-2

Development of Epigenetic Targeted Therapies in Hematological Malignancies: From Serendipity to Synthetic Lethality

Thomas Prebet, Steven D. Gore

School of Medicine

Research output: Chapter in Book/Report/Conference proceeding › Chapter

1 Scopus citations

Abstract

Hematological malignancies are the group of disease for which epigenetic targeted agents have shown the more striking benefits. Demethylating agents are considered standard of care for acute myeloid leukemia and myelodysplastic syndromes, and several histone deacetylase inhibitors are registered for the treatment of cutaneous T-cell lymphomas. In this chapter, we will describe the clinical development of these agents focusing on success and limitations and outline the preliminary results of the next generation of epidrugs targeting epigenetic regulator genes alteration rather than the epigenetic marks by itself.

Original language	English (US)
Title of host publication	Epigenetic Cancer Therapy
Publisher	Elsevier Inc.
Pages	169-187
Number of pages	19
ISBN (Electronic)	9780128002247
ISBN (Print)	9780128002063
DOIs	https://doi.org/10.1016/B978-0-12-800206-3.00008-2
State	Published - Jul 22 2015

Keywords

Histone deacetylase inhibitors
Hypomethylating agent
Leukemia
Lymphoma
Myelodysplasia

ASJC Scopus subject areas

Medicine(all)
Biochemistry, Genetics and Molecular Biology(all)

Access to Document

10.1016/B978-0-12-800206-3.00008-2

Cite this

@inbook{282e772ce2d546ffad2dbc64935d88b3,

title = "Development of Epigenetic Targeted Therapies in Hematological Malignancies: From Serendipity to Synthetic Lethality",

abstract = "Hematological malignancies are the group of disease for which epigenetic targeted agents have shown the more striking benefits. Demethylating agents are considered standard of care for acute myeloid leukemia and myelodysplastic syndromes, and several histone deacetylase inhibitors are registered for the treatment of cutaneous T-cell lymphomas. In this chapter, we will describe the clinical development of these agents focusing on success and limitations and outline the preliminary results of the next generation of epidrugs targeting epigenetic regulator genes alteration rather than the epigenetic marks by itself.",

keywords = "Histone deacetylase inhibitors, Hypomethylating agent, Leukemia, Lymphoma, Myelodysplasia",

author = "Thomas Prebet and Gore, {Steven D.}",

year = "2015",

month = jul,

day = "22",

doi = "10.1016/B978-0-12-800206-3.00008-2",

language = "English (US)",

isbn = "9780128002063",

pages = "169--187",

booktitle = "Epigenetic Cancer Therapy",

publisher = "Elsevier Inc.",

}

TY - CHAP

T1 - Development of Epigenetic Targeted Therapies in Hematological Malignancies

T2 - From Serendipity to Synthetic Lethality

AU - Prebet, Thomas

AU - Gore, Steven D.

PY - 2015/7/22

Y1 - 2015/7/22

N2 - Hematological malignancies are the group of disease for which epigenetic targeted agents have shown the more striking benefits. Demethylating agents are considered standard of care for acute myeloid leukemia and myelodysplastic syndromes, and several histone deacetylase inhibitors are registered for the treatment of cutaneous T-cell lymphomas. In this chapter, we will describe the clinical development of these agents focusing on success and limitations and outline the preliminary results of the next generation of epidrugs targeting epigenetic regulator genes alteration rather than the epigenetic marks by itself.

AB - Hematological malignancies are the group of disease for which epigenetic targeted agents have shown the more striking benefits. Demethylating agents are considered standard of care for acute myeloid leukemia and myelodysplastic syndromes, and several histone deacetylase inhibitors are registered for the treatment of cutaneous T-cell lymphomas. In this chapter, we will describe the clinical development of these agents focusing on success and limitations and outline the preliminary results of the next generation of epidrugs targeting epigenetic regulator genes alteration rather than the epigenetic marks by itself.

KW - Histone deacetylase inhibitors

KW - Hypomethylating agent

KW - Leukemia

KW - Lymphoma

KW - Myelodysplasia

UR - http://www.scopus.com/inward/record.url?scp=84939864976&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84939864976&partnerID=8YFLogxK

U2 - 10.1016/B978-0-12-800206-3.00008-2

DO - 10.1016/B978-0-12-800206-3.00008-2

M3 - Chapter

AN - SCOPUS:84939864976

SN - 9780128002063

SP - 169

EP - 187

BT - Epigenetic Cancer Therapy

PB - Elsevier Inc.

ER -

Development of Epigenetic Targeted Therapies in Hematological Malignancies: From Serendipity to Synthetic Lethality

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this